← Vanda Pharmaceuticals Inc.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Net Income (Loss) Attributable to Parent | ($18.0m) |
($15.6m)
+13.56%
|
$25.2m
+261.93%
|
$115.6m
+358.40%
|
$23.3m
-79.80%
|
$33.2m
+42.06%
|
$6.3m
-81.07%
|
$2.5m
-60.02%
|
($18.9m)
-853.29%
|
($220.5m)
-1066.53%
|
— | |
| Depreciation | $935k | $1.2m | $1.4m | $1.4m | $1.4m | $1.4m | $1.2m | $920k | $859k | $1.1m | $6.0m | |
| Amortization of Intangible Assets | $10.9m | $1.8m | $1.5m | $1.5m | $1.5m | $1.5m | $1.5m | $2.1m | $7.3m | $7.0m | — | |
| Deferred Income Tax Expense (Benefit) | ($104k) | — | — | ($87.8m) | $6.2m | $6.7m | $1.1m | ($1.3m) | ($6.5m) | $81.4m | $97.2m | |
| Share-based Payment Arrangement, Noncash Expense | $8.5m | $10.5m | $11.7m | $13.5m | $13.4m | $15.4m | $16.3m | $14.0m | $12.4m | $9.5m | $9.1m | |
| Payment, Tax Withholding, Share-based Payment Arrangement | — | — | — | — | — | — | — | — | — | $915k | — | |
| Share-based Payment Arrangement, Expense | $8.5m | $10.5m | $11.7m | $13.5m | $13.4m | $15.4m | $16.3m | $14.0m | $12.4m | $9.5m | $9.1m | |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts Receivable | $4.3m | ($2.5m) | $11.2m | ($2.3m) | $3.8m | $2.5m | $1.1m | $707k | $13.0m | $7.5m | ($14.8m) | |
| Increase (Decrease) in Inventories | ($200k) | $1.1m | ($70k) | $722k | $2.9m | $2.2m | $4.5m | $771k | $29k | $3.5m | ($1.1m) | |
| Net Cash Provided by (Used in) Operating Activities | ($8.1m) |
($2.0m)
+75.53%
|
$30.0m
+1612.15%
|
$45.9m
+53.23%
|
$51.8m
+12.68%
|
$64.2m
+24.03%
|
$32.0m
-50.19%
|
$12.8m
-59.98%
|
($15.8m)
-223.09%
|
($109.4m)
-594.56%
|
($142.3m)
-30.05%
|
|
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Property, Plant, and Equipment | $1.4m | $1.7m | $368k | $1.0m | $1.8m | $552k | $679k | $383k | $490k | $998k | ($10.7m) | |
| Debt Securities, Available-for-sale, Realized Gain (Loss) | — | — | — | — | $229k | $12k | $0 | ($655k) | $0 | $0 | — | |
| Payments for (Proceeds from) Other Investing Activities | — | ($124k) | — | — | — | — | — | — | — | — | — | |
| Net Cash Provided by (Used in) Investing Activities | ($10.1m) | ($10.1m) | ($109.7m) | ($68.3m) | ($41.5m) | ($76.7m) | $49.9m | ($12.1m) | ($17.4m) | $94.9m | $120.3m | |
| Cash flows from financing activities: | ||||||||||||
| Proceeds from Issuance of Common Stock | — | — | $100.9m | $0 | $0 | — | — | — | — | — | — | |
| Net Cash Provided by (Used in) Financing Activities | $7.8m |
$5.3m
-32.25%
|
$107.1m
+1940.11%
|
$6.3m
-94.15%
|
$5.6m
-10.06%
|
$3.5m
-36.99%
|
$734k
-79.32%
|
$0
-100.00%
|
($155k) |
($2.9m)
-1774.84%
|
($2.8m)
+4.03%
|
|
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $5k | $42k | $27.4m | ($16.1m) | $16.0m | ($9.0m) | $82.9m | $792k | ($33.5m) | ($17.5m) | $56.6m | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $5k | $42k | $61.7m | $45.6m | $61.6m | $52.6m | $135.5m | $136.3m | $102.8m | $85.3m | $56.6m | |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $5k | $42k | ($38k) | ($1k) | $53k | ($91k) | $265k | $47k | ($163k) | $23k | ($253k) | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Proceeds from Stock Options Exercised | — | $5.3m | $6.3m | $6.3m | $5.6m | $3.5m | $734k | $0 | $0 | — | — | |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, Net | — | — | — | — | — | — | — | $3.6m | $2.4m | ($90k) | — | |
| Additional Financial Items | ||||||||||||
| Income Tax Expense (Benefit) | $104k | $136k | $138k | ($86.5m) | $8.3m | $9.2m | $5.0m | $3.8m | ($4.0m) | $81.8m | — |